父源15q11.2-q13重复综合征与MKRN3过表达致青春期延迟
该研究回顾性评估4例经确认的父源15q11.2-q13重复患者,采集临床、生长、激素及影像数据,并用MS-MLPA、array-CGH及全外显子测序进行遗传学分析,以RT-qPCR检测外周血MKRN3表达并与按Tanner分期和性别匹配的对照比较。结果显示4例中3例MKRN3表达升高,临床表现为从进展缓慢的青春期延迟到低促性腺激素性性腺功能减退;作者认为父源15q11.2-q13重复与MKRN3过表达及青春期延迟相关,首次在人类中提示MKRN3剂量增加与青春期延迟的联系。
要点
- 父源15q11.2-q13重复患者可出现MKRN3过表达并伴青春期延迟。
- 青春期表型可从进展缓慢的青春期延迟至低促性腺激素性性腺功能减退。
- dup15q综合征患者应重视内分泌监测,关注青春期发育。
核心结论
- 父源15q11.2-q13重复与MKRN3过表达及青春期成熟延迟相关,首次在人类中提示MKRN3剂量增加与青春期延迟的联系,并扩展了dup15q综合征的表型谱。
研究设计与样本
- 回顾性评估4例经确认的父源15q11.2-q13重复患者,收集临床、生长、激素及影像学数据。
- 遗传学特征采用MS-MLPA、array-CGH及可行的全外显子测序分析。
- 以外周血RT-qPCR检测MKRN3表达,并与按Tanner分期和性别匹配的对照比较。
主要发现
- 全部患者均为涉及15q11.2-q13区域且确认为父源来源的重复。
- 4例中3例RT-qPCR显示MKRN3表达升高,支持潜在的基因剂量效应。
- 临床表现为从进展缓慢的青春期延迟到低促性腺激素性性腺功能减退的青春期异常。
- 1例纵向数据显示,青春进展期两个时间点的MKRN3表达水平均高于对照。
- 1例中PROKR2变异可能对表型有贡献。
临床怎么用
- 对父源15q11.2-q13重复综合征患者应进行内分泌监测,关注青春期启动与进展。
- 对青春期延迟或低促性腺激素性性腺功能减退者,可考虑评估15q11.2-q13重复及MKRN3剂量效应。
局限性
- 为回顾性研究,样本量仅4例,结论需更大样本验证。
- MKRN3过表达仅在4例中的3例观察到,基因剂量效应并非普遍。
- 1例合并PROKR2变异,表型归因存在混杂可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Duplications of the 15q11.2-q13 region are primarily associated with neurodevelopmental disorders, while their endocrine implications remain poorly defined. The imprinted gene MKRN3, located within this locus, inhibits pubertal onset, and loss-of-function variants cause central precocious puberty. However, the clinical impact of increased MKRN3 dosage remains unclear. This study investigates whether paternally derived 15q11.2-q13 duplications lead to MKRN3 overexpression and are associated with delayed pubertal maturation. MATERIALS AND METHODS: Four patients with confirmed paternal 15q11.2-q13 duplications were retrospectively evaluated. Clinical, auxological, hormonal, and radiological data were collected. Genetic characterization was performed using MS-MLPA, array-CGH, and whole-exome sequencing when possible. MKRN3 expression was assessed by RT-qPCR in peripheral blood samples and compared with Tanner and sex-matched controls. RESULTS: All patients showed duplications involving the 15q11.2-q13 region with confirmed paternal origin. RT-qPCR showed increased MKRN3 expression in three of the four patients, supporting a potential gene dosage effect. Clinically, patients presented with pubertal abnormalities ranging from delayed puberty with slow progression to hypogonadotropic hypogonadism. Longitudinal data in one patient showed that MKRN3 expression levels during pubertal progression remained elevated compared to controls at both timepoints. In one case, a variant in PROKR2 may have contributed to phenotype. CONCLUSION: Paternally derived 15q11.2-q13 duplications are associated with MKRN3 overexpression and delayed pubertal maturation. These findings suggest for the first time in humans a link between increased MKRN3 dosage and pubertal delay, expanding the phenotypic spectrum of dup15q syndrome and highlighting the importance of endocrine monitoring in affected individuals.
引用
- Petrone D, Palumbo S, Giacobbe C, et al. Pubertal delay in patients with paternally derived 15q11.2-q13 duplication syndrome and MKRN3 overexpression. J Clin Endocrinol Metab. 2026. PMID: 42755695. doi:10.1210/clinem/dgag385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。